Sign in
TerminatedPhase 1

Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)

Key facts

Who runs it
Eureka Therapeutics Inc.
Where
Duarte and Westwood, United StatesSee the 2 sites
Trial code
Status
Terminated
Phase
Phase 1
People taking part
8 people enrolled
Started
14 Apr 2021
Ended
30 Aug 2024
Type of study
Interventional
Treatments tested
  • ET140203 autologous T cell product
Record updated
8 September 2025
Why it stopped
The trial was intended to be a Phase 1/2 trial, but the sponsor terminated the trial prior to moving to Phase 2 to direct efforts to the pediatric study (ARYA-2) for this product.

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (18)Hide the full registry criteria

Who can take part

  • Histologically confirmed HCC with serum AFP >100ng/ml at time of screening and following most current line of therapy OR radiographic diagnosis of HCC with serum AFP >400ng/ml at time of screening and following most current line of therapy
  • Metastatic or locally advanced, unresectable HCC
  • Must have failed or not tolerated at least two (2) different anti-HCC systemic agents
  • Molecular Human Leukocyte Antigen ("HLA") class I allele typing confirms participant carries at least one HLA-A2 allele
  • Life expectancy of at least 4 months
  • Karnofsky Performance Scale greater than or equal to 70
  • At least 1 measurable lesion on imaging by RECIST
  • Child-Pugh A6 or better
  • Absolute neutrophil count greater than or equal to 1,500/mm\^3
  • Platelet count greater than or equal to 75,000/mm\^3

Who cannot take part

  • Clinically significant cardiac disease
  • Clinically significant pre-existing illness or active infection
  • Active autoimmune disease requiring therapy
  • History of organ transplant
  • Active malignancy other than HCC with the exception of cholangiocarcinoma (CCA) or any malignancy with an expected survival ≥ 3 years without any treatment (exception: hormone/androgen-deprivation therapy) and without any organ involvement
  • Clinically significant Central Nervous System (CNS) or neural dysfunction
  • Compromised circulation in portal vein, hepatic vein, or vena cava due to obstruction
  • Advanced HCC involving greater than 50% of the liver

Where in United States

  • City of Hope Medical CenterDuarte, United States
  • Kansas University Medical CenterWestwood, United States

About the trial

What the trial wants to find out

Open-label, dose escalation, multi-center, Phase I / II study to assess the safety of an autologous T-cell product (ET140203) in adult subjects with Alpha-fetoprotein (AFP)-positive/Human Leukocyte Antigen (HLA) A-2-positive advanced hepatocellular carcinoma (HCC).

The group in the trial

  • ET140203 TCellsTreatment being tested

    ET140203 T Cells

    Treatment: ET140203 autologous T cell product

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Open-Label, Dose Escalation, Multi-Center Phase I/II Research Trial to Assess the Safety of ET140203 T Cells and Determine the Recommended Phase II Dose (RP2D) in Adults With Advanced Hepatocellular Carcinoma (HCC) (ARYA-1)
Record updated
8 September 2025